title: Recent developments and innovations in gastric cancer.
abstract: Gastric cancer has an important place in the worldwide incidence of cancer and cancer-related deaths. It can metastasize to the lymph nodes in the early stages, and lymph node metastasis is an important prognostic factor. Surgery is a very important part of gastric cancer treatment. A D2 lymphadenectomy is the standard surgical treatment for cT1N+ and T2-T4 cancers, which are potentially curable. Recently, the TNM classification system was reorganized, and the margins for gastrectomy and lymphadenectomy were revised. Endoscopic, laparoscopic and robotic treatments of gastric cancer have progressed rapidly with development of surgical instruments and techniques, especially in Eastern countries. Different endoscopic resection techniques have been identified, and these can be divided into two main categories: endoscopic mucosal resection and endoscopic submucosal dissection. Minimally invasive surgery has been reported to be safe and effective for early gastric cancer, and it can be successfully applied to advanced gastric cancer with increasing experience. Cytoreductive surgery and hyperthermıc intraperıtoneal chemotherapy were developed as a combined treatment modality from the results of experimental and clinical studies. Also, hyperthermia increases the antitumor activity and penetration of chemotherapeutics. Trastuzumab which is a monoclonal antibody interacts with human epidermal growth factor (HER) 2 and is related to gastric carcinoma. The anti-tumor mechanism of trastuzumab is not clearly known, but mechanisms such as interruption of the HER2-mediated cell signaling pathways and cell cycle progression have been reported previously. H. pylori is involved in 90% of all gastric malignancies and Japanese guidelines strongly recommend that all H. pylori infections should be eradicated regardless of the associated disease. In this review, we present innovations discussed in recent studies.
authors.affiliation: Mehmet Mihmanli, Ufuk Oguz Idiz, Uygar Demir, Department of General Surgery, Sisli Etfal Training and Research Hospital, Istanbul 34371, Turkey.
authors.forename: Mehmet
authors.initials: M
authors.lastname: Mihmanli
authors.affiliation: Mehmet Mihmanli, Ufuk Oguz Idiz, Uygar Demir, Department of General Surgery, Sisli Etfal Training and Research Hospital, Istanbul 34371, Turkey.
authors.forename: Enver
authors.initials: E
authors.lastname: Ilhan
authors.affiliation: Mehmet Mihmanli, Ufuk Oguz Idiz, Uygar Demir, Department of General Surgery, Sisli Etfal Training and Research Hospital, Istanbul 34371, Turkey.
authors.forename: Ufuk Oguz
authors.initials: UO
authors.lastname: Idiz
authors.affiliation: Mehmet Mihmanli, Ufuk Oguz Idiz, Uygar Demir, Department of General Surgery, Sisli Etfal Training and Research Hospital, Istanbul 34371, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Alemdar
authors.affiliation: Mehmet Mihmanli, Ufuk Oguz Idiz, Uygar Demir, Department of General Surgery, Sisli Etfal Training and Research Hospital, Istanbul 34371, Turkey.
authors.forename: Uygar
authors.initials: U
authors.lastname: Demir
mesh_terms: D003131:Combined Modality Therapy; D065426:Cytoreduction Surgical Procedures; D005743:Gastrectomy; D005753:Gastric Mucosa / Q000601:surgery; D005773:Gastroscopy; D006801:Humans; D008197:Lymph Node Excision; D019060:Minimally Invasive Surgical Procedures; D009367:Neoplasm Staging; D065287:Robotic Surgical Procedures; D013274:Stomach Neoplasms / Q000473:pathology / Q000628:therapy*
keywords: Cancer; Endoscopic mucosal resection; Endoscopic submucosal resection; Gastric; Human epidermal growth factor receptor 2; Minimally invasive surgery; Neoadjuvant chemotherapy